Drug Type Bispecific T-cell Engager (BiTE) |
Synonyms DLL3-CD3 (NovaRock Biotherapeutics) |
Target |
Action stimulants, inhibitors |
Mechanism CD3 stimulants(T cell surface glycoprotein CD3 stimulants), DLL3 inhibitors(Delta-like protein 3 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Neuroendocrine Carcinoma | Preclinical | United States | 01 Nov 2024 | |
| Small Cell Lung Cancer | Preclinical | United States | 01 Sep 2024 |






